𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Challenges in management of patients with intracranial germ cell tumor and diabetes insipidus treated with cisplatin and/or ifosfamide based chemotherapy

✍ Scribed by Samina Afzal; Diane Wherrett; Ute Bartels; Uri Tabori; Annie Huang; Derek Stephens; Eric Bouffet

Publisher
Springer US
Year
2009
Tongue
English
Weight
192 KB
Volume
97
Category
Article
ISSN
0167-594X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Serum tumor marker decline is an early p
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy
✍ Barbara A. Murphy; Robert J. Motzer; Madhu Mazumdar; Vaia Vlamis; Jerome Nisselb πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 655 KB

Background. Serum tumor marker regression (alpha-fetoprotein [AFP] and human chorionic gonadotrophin (hCG]) was studied in patients treated with ifosfamide-based chemotherapy for cisplatin-resistant germ cell tumors (GCT) to investigate the role of marker regression as a predictor of treatment outco

The role of ifosfamide plus cisplatin-ba
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors
✍ Robert J. Motzer; Karen Cooper; Nancy L. Geller; Dean F. Bajorin; Ethan Dmitrovs πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 537 KB

A prospective study of four cycles of etoposide with ifosfamide and cisplatin (VIP) chemotherapy was conducted in 42 germ cell tumor (GCT) patients who were refractory to cisplatin with etoposide/vinblastine-based therapy. Forty patients were evaluable for response. Ten patients (25%) had a complete